The move follows recent additions to NTAM’s global quantitative capabilities, including the appointments of Guido Baltussen as head of quantitative strategies, international, in November 2023; Milan ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

Milan Vidojevic as Director of Quantitative Solutions, International in January 2024; and Jan Rohof as Director of Quantitative Solutions, Asia Pacific in November 2024. NTAM manages US$43 billion ...

Sports Mole previews Wednesday's Coppa Italia clash between AC Milan and Roma, including predictions, team news and possible lineups. A month on from their five-goal thriller in Riyadh ...

LISBON, Feb 5 (Reuters) - Novo Banco's planned initial public offering would be beneficial for the Portuguese banking sector, Bank of Portugal Governor Mario Centeno said on Wednesday, but he ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

CHICAGO & AMSTERDAM, February 04, 2025--(BUSINESS WIRE)--Northern Trust Asset Management (NTAM), a leading global investment management firm with US$1.3 trillion in assets under management as of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get into all the earnings and political news ...

Northern Trust Asset Management (NTAM), a leading global investment management firm with US$1.3 trillion in assets under management as of December 31, 2024, announced a major expansion of its ...

CHICAGO & AMSTERDAM–(BUSINESS WIRE)–Northern Trust Asset Management (NTAM), a leading global investment management firm with US$1.3 trillion in assets under management as of December 31, 2024, ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...